Table 6.
ICT for antibody detection validated by clinical samples.
| Virus | Biomaker | Antigen based | Antibody based (MAb or PAb) | Sensitivity (No. positive/no. tested(%)) | Specificity(No. negative/no. tested(%)) | Comment | Ref |
|---|---|---|---|---|---|---|---|
| SARS-CoV | IgG | Rec N | 44/131 (33.6) | 111/113 (98.2) | (Wu et al., 2004a) | ||
| SARS-CoV | IgG | Rec N | 42/42 (100) | 209/210 (99) | Rec N with aa 111-118 deleted | (Guan et al., 2004a) | |
| SARS-CoV | N | N (aa 244-260) |
MAb | – | 150/150 (100) | Detection limite: 7.87× 102 TCID50/mL of SARS-CoV | (Kogaki et al., 2005) |
| MERS-CoV | N | Rec N (aa 10-413) |
MAb | 62/66 (93.9%) | 18/18 (100%) | Camel nasal swabs as sample | (Song et al., 2015) |
| MERS-CoV | N | Rec N | MAb | 13/16 (81%) | 65/65 (100%) | Dromedary nasalswabs as sample |
(Chen et al., 2016) |
| SARS-CoV-2 | IgG & IgM | Rec S & N | 101/113(89) | 97/98(99) | Commercial assay (Cellex) | (Geurtsvankessel et al., 2020) | |
| SARS-CoV-2 | IgG & IgM | Rec S & N | 113/113(100) | 87/98(88) | Commercial assay (Orient/Healgen) | (Geurtsvankessel et al., 2020) | |
| SARS-CoV-2 | IgG & IgM | Rec N | 102/113(90) | 83/98(85) | Commercial assay (Intec) | (Geurtsvankessel et al., 2020) | |
| SARS-CoV-2 | IgM or IgG | synthetic S, M, and N proteins | 69/97(71.1) | 51/53(96.2) | (Shen et al., 2020) |
Rec, recombinant; N, nucleocapsid protein; Ref, reference; aa, amino acid position; -,not determined; MAb, monoclonal antibodies.